5-Alpha Reductase Inhibitors and Prostate Cancer Mortality among Men with Regular Access to Screening and Health Care.
J Bailey VaselkivCarl A CeraoloKathryn M WilsonClaire H PernarEmily M RencsokKonrad H StopsackSydney T GrobAnna PlymEdward L GiovannucciAria F OlumiAdam S KibelMark A PrestonLorelei A MucciPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2022)
Our results provide evidence that 5-ARI use is safe with respect to prostate cancer mortality in the context of regular health care access. See related commentary by Hamilton, p. 1259.